Skip to main content

Medical Policy Revision: Cryosurgical Ablation of Miscellaneous Solid Tumors Other than Liver, Prostate or Dermatologic Tumors

Effective June 18, 2018, Horizon Blue Cross Blue Shield of New Jersey will change the way we consider certain professional claims for cryosurgical ablation of certain tumors.

We encourage you to visit our Medical Policy Manual to review the guidelines of our medical policy, Cryosurgical Ablation of Miscellaneous Solid Tumors Other Than Liver, Prostate, or Dermatologic Tumors, which identify when the use of homocysteine testing is considered medically necessary.


Based on the guidelines included in our medical policy, Cryosurgical Ablation of Miscellaneous Solid Tumors Other than Liver, Prostate or Dermatologic Tumors, claims for services provided on and after June 18, 2018 will be processed as follows:

  • CPT® code 20983 will be denied as an experimental/investigational non-covered service regardless of the submitted diagnosis code(s).

Unless Horizon BCBSNJ gives written notice that all or part of the above changes have been cancelled or postponed, the changes will be applied to claims for dates of service on and after June 18, 2018.

CPT® is a registered mark of the American Medical Association.

Published on: March 20, 2018, 14:37 p.m. ET
Last updated on: March 20, 2018, 14:39 p.m. ET